A comprehensive drug discovery proposal covering in-house synthesis through compound evaluation
First written in FY2024. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-05-18.
No other company in this theme has enough history to compare yet.
- 2026-05-18ReframedFinancial results briefing materials
「Through collaboration with external partners leveraging PRISM’s PepMetics® technology, build an integrated drug discovery platform spanning target selection to compound design」
The description expanded from developing internal capabilities to building an integrated drug discovery platform spanning target selection to compound design through collaboration with external partners. - FY2025AdvancedAnnual report
「In addition to providing library compounds for collaborative development projects, we have established an in-house system covering the full drug discovery process, from the design and optimized synthesis of PepMetics compounds through PPI activity evaluation and in vitro and in vivo efficacy evaluation using tumor cells and animals, including xenograft models. We have organized an operation capable of expanding our proprietary development business by accelerating drug discovery and development and of making drug discovery proposals that meet the diversifying needs of partner companies.」
In addition to the full-scale operation of HTS and the establishment of computational chemistry and biophysics methods, an in-house system covering the full process from design through in vitro and in vivo evaluation has been established. - FY2025-H1AdvancedAnnual report
「In addition to using AI, we have completed capital investment in and established the systems for high-throughput screening (HTS), including in-house evaluation of library compounds. We are also preparing systems to measure the binding modes of compounds and proteins, among other initiatives to improve the efficiency and probability of success of drug discovery and development.」
Capital investment in and establishment of the HTS facilities and systems have been completed, and a system for measuring the binding modes of compounds and proteins has also been established. - FY2024First statedAnnual report
「In collaborative development, we can now offer comprehensive drug discovery proposals, including synthesis and evaluation conducted in-house.」
By establishing compound activity evaluation capabilities, we are seeking to shift, since the contract with Lilly, toward contracts under which we handle work through lead compounds and clinical candidate compounds.